News

Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months
However, many on Wall Street believe that better days lie ahead for Novo Nordisk. Analysts expect this obesity drug stock to ...
Endpoints News1h
No­vo Nordisk’s glob­al obe­si­ty leader is mov­ing on; Flag­ship biotech gets CEO from Schol­ar Rock
Leo Pharma is doing an extensive revamp of its leadership team as it splits product strategy and international operations ...
Novo Nordisk's Ozempic Weight Loss Jabs Could Boost UK Economy By $6 Billion, Study Finds
Making weight loss injections available to all eligible individuals in the U.K. could yield an economic boost of 4.5 billion ...
Moneyweb8m
Novo ousts CEO Jorgensen after Lilly competition hits shares
The Danish company said Jorgensen is leaving by mutual agreement with the board, though he’ll continue as chief 'for a period ...
Devdiscourse47m
Leadership Shift: Novo Nordisk CEO Jorgensen Steps Down Amid Market Struggles
Novo Nordisk CEO Lars Fruergaard Jorgensen will step down as the company faces challenges in the obesity drug market, which ...
STAT1d
Novo Nordisk strikes deal with Septerna to develop obesity pills
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
Novo Nordisk CEO to step down as Wegovy maker faces growing competition
The Danish pharmaceutical giant said Fruergaard Jørgensen would remain in his post “for a period to support a smooth ...
Why patients are being forced to switch to a 2nd-choice obesity drug
CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...
Ignore The Noise - Novo Nordisk Is A Clear Buy
Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...